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 Poor bone health with related morbidity is a major problem with Duchene 
Muscular Dystrophy (DMD). Decreased mobility and long-term corticosteroid 
therapy are involved in poor bone health in DMD. We investigated bone mineral 
density and bone metabolism in 30 steroid treated DMD patients and also 
compared mentioned factors between ambulated and non-ambulated patients.
Materials & Methods
 In this cross-sectional study, 30 boys (21 patients ambulate and 9 non-ambulate) 
with documented DMD, according to genetic analysis, were enrolled in 2015. 
Demographic characteristics, neurologic exam findings, muscle function score, 
corticosteroid dose and duration and food frequency questionnaire were recorded. 
Bone mineral density was measured with dual- energy X-ray absorptiometry 
(DEXA) on lumbar spine and left proximal femur. Serum 25-hydroxyvitamin 
D, calcium, phosphorus and parathyroid hormone (PTH) levels were measured. 
Results
Osteoporosis was found in 86.7% patients. Mean bone density in the lumbar 
spine was -1.5±0.24 and -1.4±0.27 in ambulates and non-ambulates respectively 
(P=0.7). Mean bone density at proximal femur was -3.4±0.2 in ambulates and 
-3.4±0.3 in non-ambulates (P =0.48). 
Intra-groups statistical analysis showed significant difference between bone 
mineral density at lumbar spine and proximal femur in both mentioned groups 
(P<0.05). Vitamin D deficiency was detected in 13 patients (43.3%) and its 
serum level was significantly lower in non-ambulates compared with ambulates.
Conclusion
 Considering high prevalence of vitamin D deficiency and osteoporosis in DMD 
patients, it seems vitamin D supplementation can improve vitamin D status and 
osteoporosis in these patients, especially in non-ambulates.
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Introduction
  Duchene Muscular Dystrophy (DMD) is an X-linked recessive disease that affects 
1 in 3500-6000 male births. This condition is resulting from mutations (mainly 
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subsequent accurate interventions and treatments.
Materials & Methods
This cross-sectional study was conducted during 
January to May 2015. Thirty DMD patients (documented 
by genetic analysis) were enrolled. Demographic 
characteristics, neurologic exam findings, drug history 
and muscle function score were recorded. All of the 
patients were on long-term corticosteroid therapy. The 
muscle functional grading was classified according to 
Vignos scale (grades 1-9) (14). 
Informed consent was taken from the patients and the 
study was approved by the Ethics Committee of the 
university.
BMD was measured with dual- energy X-ray 
absorptiometry (DEXA; HOLOGIC, QDR 2000, 
EXPLORER S1N 90910) at lumbar spine and left 
proximal femur in the same referral center for all 
patients. Body weight and height were measured 
before DEXA scan. The DEXA results were reported 
in lumbar spine (L1, L2, L3 and total) and proximal 
of femur (neck, trochanter, intertroch and total). BMD 
greater or equal to 2 standard deviations (Z-score) 
below age and sex related values defined osteoporosis 
(15).
BMD is reported in grams per square centimeter (a 
two-dimensional measurement). Both bone mineral 
content and the geometry (macro-architecture) of the 
site measured. Serum calcium, phosphorus, alkaline 
phosphatase (calorimetric method, bionic kit, Hitachi 
917), parathyroid hormone (ECL, Immulit 2000, 
normal range: 15-65) and serum 25-hydroxy vitamin 
D (ELISA, Algeria) level were checked for all patients. 
The severity of 25OH vitamin D deficiency was 
classified according to pre-defined standards (16).
 A food-frequency questionnaire (FFQ) was used to assess 
average intakes of 52 items of foods and beverages over 
the past year. All common food sources of calcium, 
phosphorus and vitamin D were included in FFQ.Three 
day food records were obtained additionally. Each 
food and beverage was then coded according to Iranian 
food items and analyzed for content of nutrients by 
nutritionist IV software (first Databank, Hearst Corp, 
San Bruno, Ca, USA) (17).
The study was not specifically aimed at evaluating 
deletions) in the dystrophin gene located at Xp21.2. 
leading to either an absence of protein dystrophin or 
its defect causing progressive muscle degeneration. 
Historically patients with DMD are usually wheelchair-
bound before the age from 12 yrs and often die in their 
early 20s (1-3). Although no specific causal treatments 
for DMD have been established, corticosteroids have 
decreased the progression of the disease and improve 
muscular strength (4, 5). The natural history of the 
disease can be altered by targeting the interventions 
to known manifestations and complications such as 
respiratory, cardiac, musculoskeletal and psychological 
symptoms that can lead to improvement in function, 
quality of life and longevity in children currently being 
diagnosed with DMD and raising their life expectancy 
toward their fourth decade (6-8). 
 Poor bone health is a common feature of patients with 
DMD and the cause of significant morbidity including 
increased fracture rates, bone pain, osteopenia and 
osteoporosis. It might be because of any pathological 
changes; on the other hand low level of vitamin D and/
or prolonged administration of corticosteroids can 
worsen this process (9, 10). Osteoporosis in children 
is defined by the presence of vertebral compression 
fractures without local disease or trauma, or the presence 
both a clinically significant fracture history and bone 
mineral density (BMD) greater or equal to 2 standard 
deviations (Z-score) below age and sex related values 
(11). For some patients with DMD the occurrence of a 
long bone fracture heralds the end of ambulation (12). 
Previous international courses were held in 2004 on 
the DMD patients and osteoporosis related problems. 
Experts in orthopedics, genetics, endocrinology, 
nutrition, and rehabilitation medicine were assembled 
in Birmingham, UK and Cincinnati, Ohio USA to 
review the knowledge about the prevalence and cause 
of bone fragility and to propose future directions for 
the treatment. An important meeting through the 
Atlantic area was held regarding on the importance of 
this disease and it related problems (7, 13).
  In Division of Pediatric Neurology of Tabriz Children 
Hospital, Tabriz, Iran steroids are part of the routine 
treatment of DMD care. We investigated the aspects 
of bone mineral density and bone metabolism in 30 
male patients with DMD in North-West Iran to assure 
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the fracture rate in DMD children and only history of 
fractures was sought.
Statistical analysis was performed using SPSS 17 
(Chicago, IL, USA). Univariate analysis was used to 
determine factors associated with the development 
of osteoporosis in patients. Chi-square and Fisher’s 
exact tests were used to compare determined low bone 
mineral density between ambulate and non-ambulate 
Bone Mineral Density and Bone Metabolism in Patients with Duchenne Muscular Dystrophy 
groups. Differences were considered significant at 
P<0.05.
Results
 Thirty boys with DMD were enrolled. The mean age 
of the patients was 11±3.6 and mean age of symptom 
onset was 5.1±2 yr. Functional grading of subjects is 
presented in Table 1.
Table 1: Functional levels the study subjects
Grade     Functional level N (%)
1 Walks unassisted and climbs stairs without assistance
2 Walks unassisted and climbs stairs with aid of railing
3 Walks unassisted and climbs stairs slowly with aid of railing (>25s for eight standard 
steps)
4 Walks unassisted and rises from chair but cannot climbs stairs
5 Walks unassisted but cannot rise from chair or climb stairs
6 Walks only with assistance or walks independently with long leg braces
7 Walks in long leg braces but requires assistance for balance
8 Stands in long leg braces but unable to walk even with assistance
9 Is in a wheelchair
Patient with scale 1-5 Classified as ambulate (n=21), 
and with scale 6-9 non-ambulate (n=9). The mean age 
of loss of ambulation was 9.1±0.9 yr. 
Twenty six patients (86.7%) had osteoporosis 
according to bone densitometry reports. The prevalence 
of osteoporosis was not significantly different between 
two ambulatory and non-ambulatory groups (P>0.05). 
The mean lumbar spine bone density z-score was 
-1.5±0.22. The mean proximal femur bone density 
z-score was -3.4±0.25. Bone mineral density in the 
proximal femur was more profoundly diminished than 
that in the lumbar spine in both ambulatory and non-
ambulatory group (P<0.05). 
History of previous fracture was obtained in 7(23.3%) 
patients. All of the patients were on long-term 
corticosteroid therapy (17-79 months, mean 48±31 
months) and the mean dose of corticosteroid was 
0.4±0.15mg/kg/day. Duration of steroid therapy had 
significant effect on osteoporosis prevalence (P=0.03).
Vitamin-D deficiency was detected in 13 patients 
(Table 2).
Table 2: The range of vitamin-D deficiency in 30 DMD patients
Range Degree of deficiency Number of patients Percentage
<10 nmol/l Severe deficiency 2 6.7
10-20 nmol/l Deficiency 8 26.7
20-30 nmol/l Insufficiency 3 10
>30 nmol/l Sufficient or normal  17 56.7
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was within normal range mean=9.7±0.3. Dietary intake 
of the vitamin in all patients was lower than 15 µg/day. 
Serum phosphorus levels were within normal limits in 
all patients (normal range 4-6). PTH level was 40±25 
(normal range15-65). Main characteristics of the two 
groups of patients (ambulate and non-ambulate were 
compared on Table 3.
 Serum vitamin-D level was more profoundly diminished 
in non-ambulates (88%) comparing with ambulates 
(23%) (P=0.008).There was no statistically significant 
correlation between serum level of vitamin-D and bone 
density (P=0.11).
 The mean dietary calcium intake of patients was 
1100±500, 18 patients (60%) had calcium dietary lower 
than 1200 mg/d and in all patients serum calcium level 




Osteoporosis 18/21(85%) 8/9(88%)       1
Bone density(g/cm2)
(Lumbar spine)
-1.5±0.24 -1.4±0.27       0.7
Bone density(g/cm2)
(proximal femur)
-3.4±0.2 -3.4±0.3        0.48
Vit-D deficiency 5/21(23%)  8/9(88%)        0.008
Discussion
 The problem of deteriorating bone health has been 
recognized for a long time in patients with DMD but 
it is only now becoming a topic of research. Two 
international workshops were organized in 2004 to 
address the growing treatment of low BMD in patients 
with DMD. There are several mechanisms involved in 
poor bone health. Reduced muscle tension on bone and 
consequent loss of muscular strength is likely significant, 
however there are many other potential mechanisms, 
involving chronic inflammation that is a characteristic 
of DMD wherein muscles lack dystrophin, activation 
of pathways affecting osteoclastogenesis, calcium 
homeostasis alteration, long-term steroid therapy as 
well as changes in vitamin D status (18, 19).
 Approximately 87% of patients with DMD from our 
study presented low bone mineral density; corroborating 
other DMD studies that reported decreases in BMD. In 
a study using Z-score as a measure, eight out of ten of 
DMD non- steroid treated patients had osteoporosis 
in the proximal femur (20). Twenty two DMD non- 
steroid treated patients presented lower BMD before the 
loss of ambulation and it was correlated with muscular 
weakness (21). Binachi et al. studied 32 patients with 
DMD and 22 of them were treated with a long-term 
steroid, ten cases received no steroids, all of the patients 
had bone mineral density lower (z-score) than normal 
for their age and even lower in the steroid treated 
patients. There was a significant decrease in their spinal 
bone mineral density and low 25-hydroxyvitamin D 
levels; also, there was an increased bone turnover 
markers especially in the steroid-treated group (22). 
Low bone mineral density has also been reported for 
steroid treated and non- steroid treated DMD patients 
in other studies (23).
 Larson et al. investigated fracture prevalence and 
osteoporosis contributors in 41 patients with DMD. 
They showed that 18(44%) from 41 patients had 
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PTH levels were within normal range for all subjects. 
Significantly low levels of 25(OH) D were found in 
patients group compared with the control group (27). 
75% of 117 patient with DMD had inadequate vitamin 
D level and 14% had severe deficiency (28). 
 Bianchi et al. published a follow-up study of 33 
children with DMD being treated with a fixed dose of 
prednisone. Patients were observed for the first year 
and were subsequently treated with vitamin D3 plus an 
adjustment of dietary calcium for two additional years. 
During the year of observation, bone mineral content 
and BMD decreased in all patients. At the end of 
therapy there was a significant increase in bone mineral 
content and BMD in 65 % of cases (22). 
These results raise important components about the 
bone disorder in patients with DMD. Components of 
osteomalacia are suggested by observed improvement 
of low bone mineral content and BMD with vitamin D 
repletion. 
However, the particular part of osteoporosis have been 
discovered but the full correction using vitamin D and 
calcium nutritional status should be studied more in 
future research. 
 The bone related disease in DMD not only are due 
to the osteoporotic nature of this disease but also it 
might be found in other disease such as osteomalacia. 
In most of reported cases a mixture of these two illness 
were presented simultaneously. This adds complexity 
to the choice of possible therapeutic approaches 
and emphasizes the importance of achieving a better 
understanding of the causes of the DMD bone loss in 
DMD patients (29).
As for limitation of our study, urinary calcium and 
phosphorus excretion were not measured also evaluation 
of bone fracture was not surveyed radiologically and 
only history of fractures was sought. Due to ethical 
point we could not design case – control study. 
In conclusion, there are a higher frequency of the 
vitamin D deficiency and osteoporosis in DMD patients 
although osteoporosis severity was not affected by 
muscle function and ambulation. So it seems that 
vitamin D supplementation can improve vitamin D 
status and osteoporosis in these patients, especially in 
non-ambulates.
sustained at least one fracture, and demonstrated that 
lumbar spine bone density was affected by the loss 
of ambulation in contrast to proximal femur that was 
markedly diminished even in ambulatory phase. In our 
study the mean bone density in the proximal femur is 
more profoundly diminished than that in the lumbar 
spine in both ambulated and non-ambulated patients 
but in contrast to Larson study osteoporosis severity 
was not affected by muscle function (24).
 Although corticosteroids slow the progression of the 
disease, long-term treatment results in osteoporosis, 
though trabecular bone demineralization and increasing 
incidence of bone fractures. The possible adverse side 
effects of corticosteroids therapy directly on bone are 
difficult to separate from those which may be indirectly 
beneficial to muscular strength. Indeed BMD appears 
to be diminished at a very early age regardless of 
steroid use (25).
An estimated 20%-25% of boys with DMD experience 
a long bone fracture. In UK, 158 patients with DMD 
presented fracture prevalence of 20.9%. The use of 
steroid was not shown to increase the risk of fracture in 
this investigation (11). History of previous fracture in 
our study was obtained out of 7(23.3%) patients. The 
mean duration of corticosteroid therapy was 4±2.6 yr 
in our study having statistically significant effect on 
osteoporosis prevalence (P=0.03). 
 Diet is extremely important when considering calcium 
and vitamin -D status in children. Sunshine exposure is 
another important source of this vitamin. Children with 
DMD may spend less time exposed to sunshine than 
other children resulting in lower vitamin -D synthesis 
and are consequently dependent on dietary intake and 
supplementation. The maximum net calcium balanced 
is achieved with dietary intake of 1200-1500 mg/d and 
vitamin -D intake of 15 μg/d (26). In the present study, 
60% of patients had calcium dietary intake lower than 
1200 mg/d and all of the patients had vitamin -D dietary 
intake lower than 10 μg/d.
 In the present study, 43.3% had inadequate vitamin D 
level and 6.7% showed severe vitamin D deficiency. 
Serum vitamin -D level was more profoundly 
diminished in non-ambulates group. In a study, with 
24 DMD patients and 24 age-matched healthy boys the 
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